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Abstract
Introduction: Matrix metalloproteinases (MMPs) are implicated in the destruction of the joint and have been shown to
be strongly associated with inflammation in rheumatoid arthritis (RA). Circulating MMPs have also been associated with
cardiovascular disease in the general population, and are predictive of cardiovascular mortality. The purpose of the
present study was to determine whether circulating levels of MMPs are predictive of mortality in RA.
Methods: A multiplex suspension array system (Luminex®) was used to measure levels of MMPs (1, 2, 3, 8 and 9)
in sera taken at recruitment of RA patients (n = 487) in a study of factors associated with mortality in RA. Patients
were tracked on the National Health Service Central Register for notification of death, and the relationship between
baseline MMP levels and mortality was analysed using Cox proportional hazards regression analysis.
Results: At the time of follow-up, 204/486 patients had died, of which 94 (46.1%) had died of circulatory diseases,
49 of malignancy (24.0%), and 42 (20.6%) of respiratory diseases. In a stepwise analysis which included all MMPs,
only MMP-8 was significantly associated with all cause mortality (P = 0.0007, 0.6% hazard ratio increase per ng/ml).
No association was found between MMP levels and mortality due to circulatory disease or malignancy. However
MMP-8 levels were strongly associated with mortality due to respiratory disease (P < 0.0001, 1.3% hazard ratio
increase per ng/ml). The association with respiratory disease related mortality remained highly significant in
multivariate models which included smoking as well as markers of severity and disease activity such as rheumatoid
factor, nodular disease, and C-reactive protein (CRP).
Conclusions: The serum level of MMP-8 is a strong predictor of mortality in RA, especially that due to respiratory
disease. This finding is consistent with increased activation of neutrophils in RA and identifies serum MMP-8 as a
useful marker for increased risk of premature death.
Introduction
Many studies have shown that the mortality rate is
increased in patients with rheumatoid arthritis (RA) com-
pared with the general population [1-6]. Causes of death
in RA are similar to those in the general population but
there is an increased risk of death due to cardiovascular
disease (CVD), and an excess of deaths due to infection,
much of which is due to lower respiratory tract infections
[1,2,7-12].
Markers of inflammation such as erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP) and soluble
tumour necrosis factor receptors have been shown to be
predictive of mortality in RA [2,3,5,7-9,13], but many
other markers associated with the disease process have
not been investigated. Some of these may provide alter-
native or better predictors of early mortality. One such
group of markers are the matrix metalloproteinases
(MMPs). These are implicated in the destruction of the
joint and have been shown to be strongly associated
with inflammation and disease activity in RA [14-18].
Circulating MMPs have also been associated with CVD
and atherosclerotic plaque instability in non-RA patients
[19-25], and have been shown to be predictive of cardio-
vascular mortality [20,25].
We postulated that elevated levels of circulating
MMPs in RA patients may be associated not only with
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increased rheumatoid disease activity and severity, but
may also predict premature mortality. We have thus
investigated the relationship of circulating levels of
MMPs with all-cause, and cause-specific mortality, and
determined whether any relationship between mortality
and MMP levels was independent of traditional risk fac-
tors and other markers of inflammation and disease
severity.
Materials and methods
Study population
This was a follow up study of a cohort of RA patients from
North Staffordshire, England, recruited between 1993 and
1998 to investigate long-term outcome and mortality in
patients attending a hospital-based clinic at the Haywood
Rheumatology Centre. Consecutive cases were selected
from clinics of confirmed RA patients who satisfied the
1987 American College of Rheumatology criteria for RA
[26]. Baseline assessments included the disability index of
the Stanford health assessment questionnaire (HAQ) [27],
presence of erosions, CRP and ESR levels, IgM rheumatoid
factor (RF), and presence or absence of nodular disease.
Age, sex, disease duration at recruitment, and history of
current or past cigarette smoking was also recorded. As an
indication of pre-existing CVD at the time of recruitment,
patients were stratified according to whether or not they
were taking any drugs for cardiovascular problems. This
included patients taking drugs for cardiac and non-cardiac
conditions, the latter including cerebrovascular disease
and peripheral vascular disease. Patients taking drugs for
hypertension alone were not included in this group. The
study was approved by the North Staffordshire local
research ethics committee.
The treatment of patients at baseline reflected standard
UK practice for management of hospital-based RA patients
as outlined in published guidelines [28]. Patients were
receiving anti-inflammatory and/or anti-rheumatic therapy,
with the majority of patients (> 90%) being treated with
one or more disease modifying anti-rheumatic drugs
(DMARDs). DMARDs were chosen according to physi-
cian’s preference, using the standard practice at the time of
sequential monotherapy and combination therapy for more
severe disease. The most common combination was meth-
otrexate and sulphasalazine. Steroids and cytotoxic drugs
such as azathioprine or cyclophosphamide were received
by a small minority of individuals (< 5%). A number of
patients (8%) were treated with anti-TNF agents during the
latter years of the study (from 2002). These patients all ful-
filled the United Kingdom National Institute of Clinical
Excellence (NICE) criteria for use of anti-TNF therapy.
Survival follow up
All patients were registered on the NHS Central Regis-
ter (NHSCR), a computerised registry of the records of
all patients registered with a general practitioner in
England and Wales. Access to this registry was obtained
via the Office for National Statistics (ONS), General
Register Office, Southport, UK. Patients were tracked on
the NHSCR, and notification of patient deaths was
obtained from the ONS within 1 month of death.
Causes of death were coded by the ONS, using the
International Classification of Diseases Ninth Revision
(ICD-9) [29] up until 31 December 2000, and ICD-10
after this date. Patients were followed up to 31 Decem-
ber 2011.
Multiplex MMP assays
Sera were separated from bloods collected in plain glass
Becton Dickinson (BD) (Becton Dickinson, Oxford,
Oxfordshire, UK) Vacutainer® tubes at study entry.
Bloods were allowed to clot for 60 minutes at room tem-
perature before serum separation and storage at -70o C
until required. Measurement of MMP-1, 2, 3, 8 and 9
levels was performed on the serum samples using Fluoro-
kine MAP multiplex kits (R&D Systems, Minneapolis,
MN, USA) and was read on a Luminex® suspension
array system (Bio-Plex 200™, Bio-Rad (Bio-Rad Labora-
tories, Hemel Hempstead, Hertfordshire, UK)). Sample
preparation and assay procedure were followed according
to the manufacturer’s recommendation. Heteroblock
(Omega Biologicals, Bozeman, MT, USA) was added at a
concentration of 150 ug/ml into the sample diluent prior
to assay, to block any non-specific binding to RF [30]. All
samples were run in duplicate with the appropriate stan-
dards on 96-well microplates. The limit of detection for
each of the MMPs was as follows: MMP-1, 0.04 ng/ml;
MMP-2, 0.03 ng/ml; MMP-3, 0.01 ng/ml; MMP-8, 0.04
ng/ml; MMP-9, 0.74 ng/ml. The intra- and inter-assay
coefficients of variation for each of the MMPs were
between 1.5 and 9.2%, and 6.2 and 15.2% respectively.
Statistical analysis
Spearman’s rank correlation was used to assess the rela-
tionship between MMP levels and measures of disease
activity and severity. The Mann-Whitney U-test was used
to determine baseline differences in MMP levels between
patients with and without nodular or erosive disease,
between smokers and non-smokers and between surviv-
ing and non-surviving patients. The association between
serum MMP levels and mortality risk was investigated
using Cox proportional hazard regression analyses
adjusted for age, sex and disease duration at baseline.
The time intervals for those patients who were alive at
the end of the study period and those who were lost to
follow up were censored. The censoring date was the
date of the last hospital visit. Since mortality data are
recorded centrally in the UK, we were able to collect
mortality data on all patients entered into the study, and
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patients lost to follow up without a documented death
could be censored with some degree of certainty. Multi-
variate stepwise models were used to assess the predictive
value of MMP levels compared with other potential base-
line risk factors (such as, RF, nodules, CRP, ESR, HAQ,
taking CVD drugs, smoking status). Separate analyses
were carried out on the risk of mortality related to each
of the major causes of death in RA, namely circulatory,
malignant and respiratory diseases. In these analyses the
data on subjects who died of other causes, and the data
on those who were still alive at last follow up were
censored.
Kaplan-Meier curves were plotted to illustrate survival
in relation to median MMP levels at baseline. All data
were analysed using Number Cruncher Statistical Soft-
ware package for Windows (NCSS 2000, NCSS Statisti-
cal Software, Kaysville, UT, USA), and GraphPad Prism
software (version 1.03, GraphPad Software Incorporated,
San Diego, CA, USA).
Results
Characteristics of RA patients
The baseline clinical features of the cohort are sum-
marised in Table 1. Of the 487 patients recruited there
were 204 deaths (41.9%), of which 86 were men and 118
were women. For patients who died the median survival
time from study baseline was 6.9 years (interquartile
range (IQR) 3.6 to 12.1). For survivors the median fol-
low up period from baseline was 16.2 years (IQR 5.9 to
17.2).
Main causes of death
The three major causes of death were due to circulatory
disease (94/204, 46.1%), neoplasia (49/204, 24.0%) and
respiratory diseases (42/204, 20.6%). Of the 94 patients
who died from circulatory disease, 62 were due to heart
disease (mainly ischaemic heart disease, congestive heart
failure, or left ventricular failure), and 19 were due to
cerebrovascular disease. The main cause of respiratory
disease related mortality was pneumonia (29/42). In this
group, pneumonia was recorded as the only cause of
death, or the only cause with RA as a contributing
cause in 23/29 patients. Of the remaining six patients
with pneumonia, three also had longstanding chronic
obstructive pulmonary disease (COPD), one had pul-
monary fibrosis, one had CVD and one was associated
with sepsis.
Relationship between MMP levels and patient
characteristics at baseline
There was a positive correlation between the levels of all
the MMPs apart from MMP-2 (Additional file 1). Compar-
ison of MMP levels in men and women showed a signifi-
cantly higher median level of MMP-3 (28.1 v 21.2 ng/ml,
P = 0.00008), MMP-8 (23.37 v 17.96 ng/ml, P = 0.0008)
and MMP-9 (435.5 v 363.5 ng/ml, P = 0.001) in men. The
levels of MMP-1, MMP-2 and MMP-3 showed a signifi-
cant increase with age (Rs ≥ 0.106, P ≤ 0.01), independent
of disease duration (Additional file 2). Most measures of
disease activity and severity (ESR, CRP, HAQ, Larsen
score, visual analogue (VAS) pain score) were positively
correlated with levels of all MMPs apart from MMP-2
(Additional file 2). The latter showed a negative correlation
with CRP and the VAS pain score. No correlation was
found between IgM RF titres and MMP levels. Patients
with erosive disease had significantly higher levels of
MMP-3 than those with non-erosive disease (25.46 v 15.35
ng/ml, P = 0.006), but no difference was found for other
MMPs. The association with MMP-3 remained significant
after adjusting for age, sex and disease duration (data not
shown). No difference in MMP levels was found between
patients with or without nodular disease. Patients who
were taking one or more drugs for CVD at baseline had
significantly higher levels of MMP-2, MMP-8 and MMP-9
than patients not taking these drugs (146.3 v 131.1 ng/ml,
P = 0.007, 26.67 v 20.32 ng/ml, P = 0.02, and 471.5 v
413.7, P = 0.049 respectively). However, in a stepwise ana-
lysis adjusted for age, sex and disease duration, there was
only an association with MMP-9 levels (data not shown).
Patients that had ever smoked also had higher levels of
MMP-8 and MMP-9 than those who had never smoked
(22.05 v 17.46 ng/ml, P = 0.015, and 411.2 v 344.8 ng/ml,
P = 0.004 respectively).
Relationship between MMP levels and mortality
Compared with surviving patients, baseline levels of
MMP-2 were significantly higher in patients who died
during follow up (Table 2). Stratification by causes of
death also demonstrated that higher levels of MMP-2
were found in patients who later died from circulatory
disease, but higher levels of MMP-8 were found in
patients who died from respiratory disease. Baseline
MMP-1 levels were lower in patients who later died from
malignant disease, but this association disappeared after
Table 1 Characteristics of rheumatoid arthritis (RA)
patients at baseline
Number 487
Male/female 194/293
Age (SD)* 58.3 (12.5)
Age of onset (SD)* 48.9 (13.0)
Duration, years (SD)* 9.4 (8.3)
Rheumatoid factor positive (%) 283 (58.1)
Nodules (%) 84 (17.2)
Erosive (%) 405 (83.2)
HAQ (IQR) 1.625 (1.0, 2.125)
*Mean values and standard deviation (SD). HAQ, Health Assessment
Questionnaire; IQR, interquartile range.
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adjusting for age, sex and disease duration (data not
shown). The association of high baseline MMP-2 levels
with patients who later died also disappeared after adjust-
ing for age, sex and disease duration. However, the asso-
ciation of high MMP-8 levels with patients later dying of
respiratory disease remained after such adjustment (P =
0.01).
We next investigated whether the mortality risk
increased with increasing levels of MMPs. Separate Cox
analysis for each MMP, with adjustment for age, sex
and disease duration demonstrated significant increases
in the hazard ratio (HR) with increasing levels of MMP-
8 and MMP-9 (Table 3). No association with MMP-2
levels was seen in Cox models adjusted for age. Analyses
of cause-specific mortality demonstrated significant
associations of MMP-8 and MMP-9 with mortality due
to respiratory disease (Table 4). No associations were
found with any MMPs for deaths due to circulatory dis-
ease or neoplasia.
Multivariate survival analysis
In stepwise Cox proportional hazards regression models
that included all MMPs, only MMP-8 was found to be
significantly associated with all-cause mortality (HR =
1.006 per ng/ml, 95% CI 1.002, 1.01, P = 0.003). Further
multivariate analyses including other risk factors
revealed that MMP-8 level was predictive of mortality
independently of age, smoking at baseline, nodular dis-
ease, and taking CVD drugs at baseline, all of which
were associated with all-cause mortality (Table 5). Other
disease activity and severity markers (CRP, ESR, HAQ,
RF, Larsen score) were excluded due to non-significance
in stepwise analysis (Table 5).
Mortality due to circulatory diseases was not asso-
ciated with levels of any MMP, although when mortality
due to heart disease alone was analysed a significant
association with baseline MMP-9 levels was found (HR
1.0013 per ng/ml, P = 0.01). This remained significant
(P = 0.01) after adjusting for smoking at baseline and
nodular disease, but significance was lost when adjusted
for patients taking CVD drugs at baseline. The latter
association was highly significant (HR 4.60, 95% CI 2.39,
8.94, P < 0.0001). As in the case of all-cause mortality,
we found that age, smoking at baseline and nodular dis-
ease were all significantly associated, with or without
adjustment for taking CVD drugs.
Mortality due to neoplasia was not associated with
levels of any MMP. The most significant predictors were
older age, and smoking at baseline (data not shown).
Multivariate analysis of mortality due to respiratory dis-
ease showed that MMP-8 level was a highly significant
predictor along with age, nodular disease and presence of
RF (Table 5). Although significant in univariate analysis,
MMP-9 levels were not significantly associated in a
model that also included MMP-8 levels. Smoking and
measures of inflammation were not associated. Separate
analyses of patients who had died from pneumonia or
from other causes of respiratory disease demonstrated a
significant association with MMP-8 levels in both cases,
Table 2 Circulating baseline levels of metalloproteinases (MMPs) in surviving and non-surviving rheumatoid arthritis
patients
Survivors Non survivors by major causes of death
All causes Circulatory disease Neoplastic disease Respiratory disease
Number 283 204 94 49 42
MMP-1 3.35 3.60 3.42 2.52 4.93
MMP-2 129.09 141.11 150.08 137.51 139.73
MMP-3 23.22 27.42 25.63 27.89 27.42
MMP-8 20.03 20.50 18.67 18.55 25.16*
MMP-9 384.81 375.82 377.44 386.38 449.75
Serum levels of MMPs (ng/ml) are medians.*P (adjusted for age, sex and disease duration) = 0.01 (compared with surviving patients).
Table 3 Association of baseline levels of individual
metalloproteinaises (MMPs) with all-cause mortality
MMP (ng/ml) Hazard ratio (95% CI) P
MMP-1 1.003 (0.99, 1.01) 0.3
MMP-2 1.0005 (0.99, 1.001) 0.7
MMP-3 0.999 (0.998, 1.000) 0.07
MMP-8 1.006 (1.002, 1.01) 0.003
MMP-9 1.005 (1.00, 1.001) 0.04
Separate Cox proportional hazard regression analyses were carried out for
each MMP with adjustment for age, sex and disease duration at baseline.
Table 4 Association of baseline levels of individual
metalloproteinases (MMPs) with respiratory disease-
related mortality
MMP (ng/ml) Hazard ratio (95% CI) P
MMP-1 1.007 (0.99, 1.001) 0.1
MMP-2 1.000 (0.99, 1.000) 1.0
MMP-3 0.997 (0.994, 0.999) 0.3
MMP-8 1.013 (1.005, 1.02) < 0.0001
MMP-9 1.002 (1.00, 1.004) 0.002
Separate Cox proportional hazard regression analyses were carried out for
each MMP with adjustment for age, sex and disease duration at baseline.
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although the number of patients who had died from
causes other than pneumonia was small (n = 13) (Table 6).
Figure 1 illustrates the survival of patients in relation
to the median cutoff level for MMP-8 (20.07 ng/ml) at
baseline using Kaplan-Meier analysis to generate survival
curves based on mortality due to respiratory disease
(Figure 1A) or pneumonia alone (Figure 1B). Levels
equal to and above the median were associated with sig-
nificantly worse survival (HR 2.63, 95% CI 1.38, 5.05, P
= 0.003 and HR 4.44, 95% CI 1.86, 10.59, P = 0.0007
respectively, after adjustment for age, sex and disease
duration at baseline).
Discussion
Our data indicate that the serum level of MMP-8 (neutro-
phil collagenase) is a strong predictor of mortality in RA,
especially that due to respiratory disease. As far as we are
aware, this is the first study to identify a biomarker that is
predictive of respiratory disease-related mortality in RA.
Age, nodular disease and presence of RF were also predic-
tive but the MMP-8 association was independent of these.
Although the majority of deaths in this group of patients
were due to pneumonia, separate cause-specific analyses
revealed that MMP-8 levels were associated with mortality
from both pneumonia and other forms of respiratory dis-
ease. The latter included pulmonary fibrosis, COPD, bron-
chitis, and bronchiectasis, but these were analysed as a
single group since the numbers were too small to investi-
gate specific sub-groups. Further research on larger
cohorts of patients will be needed to determine whether
MMP-8 levels are predictive of mortality from specific
respiratory diseases other than pneumonia.
Apart from MMP-8 and age, the other baseline para-
meters most strongly associated with mortality in this
study were smoking, (all-cause mortality, cancer mortal-
ity), taking CVD drugs (all cause-mortality, cardiovascular
mortality), nodular disease (all-cause mortality, respiratory
disease mortality), and RF (all-cause mortality, respiratory
disease mortality). The findings on all-cause mortality are
consistent with previous studies in RA. Although we and
others have shown that higher levels of MMP-8 are asso-
ciated with smoking in RA and other conditions [31,32],
our results suggest that the association of MMP-8 with
all-cause and respiratory disease mortality is independent
of smoking.
It is interesting that none of the other MMPs examined
here were associated with mortality after adjusting for
MMP-8 levels or age, sex and disease duration, even
though all of the MMPs, apart from MMP-2, showed sig-
nificant correlations with inflammatory and disease
severity markers, and the literature on non-RA popula-
tions has reported associations of MMP-2, MMP-3 and
MMP-9 levels with CVD [19-24]. In this study we found
that the baseline levels of MMP-2 were significantly
higher in patients who subsequently died in the follow up
period, but the association disappeared after adjusting for
age. This can be explained by the significant association
between age and MMP-2 levels seen in the correlation
analyses. Although we found no association of MMP
levels with mortality from circulatory diseases in general,
we did find that MMP-9 levels were associated with mor-
tality specifically due to heart disease. This association
disappeared after adjusting for patients taking CVD
drugs at baseline. This can probably be explained by our
Table 5 Multivariate baseline predictors of all-cause and
respiratory disease-related mortality in rheumatoid
arthritis patients
Step and variable Hazard ratio (95% CI) P
All-cause mortality
1. Age (years) 1.08 (1.06, 1.09) < 0.0001
2. Nodular disease 2.05 (1.27, 3.31) < 0.0001
3. Taking CVD drugs 1.96 (1.25, 3.05) 0.002
4. Smoking at baseline 1.97 (1.25, 3.10) 0.007
5. MMP-8 (ng/ml) 1.01 (1.002, 1.02) 0.01
Respiratory disease mortality
1. Age (years) 1.12 (1.08, 1.16) < 0.0001
2. MMP-8 (ng/ml) 1.013 (1.006, 1.02) < 0.0001
3. Nodular disease 2.76 (1.38, 5.50) 0.0002
4. Rheumatoid factor 2.57 (1.18, 5.58) 0.02
Stepwise Cox proportional hazards regression. Baseline variables included in
the analyses were age, sex, disease duration, MMP-8 (ng/ml), rheumatoid
factor (+/-), nodular disease (+/-), C-reactive protein (mg/l), erythrocyte
sedimentation rate (mm/h), Health Assessment Questionnaire (score 0 to 3),
Larsen score, taking drugs for cardiovascular disease (CVD) (+/-) and smoking
at entry (+/-). Only significant variables retained in the stepwise analysis are
shown.
Table 6 Multivariate baseline predictors of mortality due
to pneumonia and mortality due to other respiratory
diseases in rheumatoid arthritis patients
Step and variable Hazard ratio (95% CI) P
Mortality due to pneumonia
1. Age 1.08/yr (1.05, 1.17) < 0.0001
2. MMP-8 (ng/ml) 1.012 (1.010, 1.025) 0.0002
3. Nodular disease 2.36 (1.01, 5.53) 0.01
4. Rheumatoid factor 2.66 (1.03, 6.82) 0.05
Mortality due to other respiratory
diseases*
1. Age 1.09/yr (1.03, 1.16) 0.006
2. Nodular disease 4.45 (1.55, 12.81) 0.006
3. MMP-8 (ng/ml) 1.016 (1.004, 1.03) 0.004
Stepwise Cox proportional hazards regression. Baseline variables included in the
analyses were age, sex, disease duration, metalloproteinase (MMP)-8 (ng/ml),
rheumatoid factor (+/-), nodular disease (+/-), C-reactive protein (mg/dl),
erythrocyte sedimentation rate (mm/h), Health Assessment Questionnaire (score
0 to 3), Larsen score, taking drugs for cardiovascular disease (CVD) (+/-) and
smoking at entry (+/-). Only significant variables retained in the stepwise analysis
are shown. *Includes pulmonary fibrosis (n = 3), chronic obstructive pulmonary
disease (n = 4), bronchitis (n = 2), bronchiectasis (n = 3) and asthma (n = 1).
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data showing that these particular patients had signifi-
cantly higher levels of MMP-9, and is consistent with
previous studies in no-RA populations showing higher
levels of MMP-9 in heart disease [19-21,24].
The mechanisms behind the association of MMP-8
levels with mortality from respiratory disease are likely to
involve the tissue destructive effects of this MMP. Several
cell types may contribute towards the levels of MMP-8
but the major source is most likely to be activated neu-
trophils. Many previous studies have demonstrated the
likely role of neutrophil-derived MMPs in the pathogen-
esis of respiratory diseases, including acute respiratory
distress syndrome or acute lung injury [33,34], COPD
[35,36], cystic fibrosis [37], interstitial lung disease [38],
idiopathic pulmonary fibrosis [39] and bronchiectasis
[40,41]. Furthermore, pulmonary MMP concentrations
have been shown to be elevated in patients with hospital-
acquired pneumonia [42,43]. All of these conditions are
characterized by an influx of neutrophils into sites of
inflammation and subsequent pulmonary tissue injury,
the severity of which is associated with MMP levels
[39,40,42,43].
It is interesting in this study that measurement of
MMP-8 levels at a single time point was predictive of
long-term mortality, even though in many cases the
levels were measured years before death. One possibility
is that elevated MMP-8 levels may reflect chronic
ongoing neutrophil activation, which may persist for
many years in RA. Peripheral blood neutrophils in RA
patients have been reported to be primed but show func-
tional impairment in Fc-mediated generation of reactive
oxygen species [44]. This has been suggested to account
for the increased susceptibility to bacterial infection in
patients with severe RA and may explain the increase in
respiratory diseases such as pneumonia. The presence of
high-risk bacteria in patients with hospital-acquired
pneumonia has been shown to be associated with signifi-
cantly higher MMP-8 and MMP-9 levels and activity in
the bronchoalveolar lavage fluid [42,43]. It has also been
reported that artificial ventilation may further promote
protease activation [43,45].
There are a number of possible limitations to the pre-
sent study. Apart from determining which patients were
taking CVD drugs, other comorbidities were not
recorded at baseline. Various comorbid conditions may
be associated with elevated levels of MMPs, so these may
represent unmeasured confounders. The information on
patients taking drugs for CVD problems allowed us to
provide an estimate of patients suffering from cardiovas-
cular morbidity at the time of recruitment [46]. However,
this may have been and under- or overestimate of the
amount of cardiovascular morbidity present since some
patients with CVD may not be taking any specific CVD
drugs or may have stopped them (for example after myo-
cardial infarction. Others may have been taking certain
drugs as a preventative measure because of increased car-
diovascular risk. Nonetheless our data show that patients
on CVD drugs at baseline were significantly more likely
to die from all-cause mortality, and heart disease in parti-
cular, than patients not on these drugs. Our data also
show that patients taking CVD drugs at baseline had
higher levels of MMP-2, 8 and 9 than patients not taking
these drugs. However this does not explain the increased
risk associated with elevated MMP-8 level, since this was
associated with all-cause mortality independent of taking
CVD drugs, and the latter were not associated with mor-
tality from respiratory disease in models in which MMP-
8 levels were highly significant.
A second possible limitation is the generalisability of the
findings to the wider RA community since the patients
studied were hospital-recruited and the study population
was likely to include patients with more severe disease.
The treatment of patients at baseline and during the fol-
low up period also underwent changes in standard UK
practice for treatment of hospital-based RA patients over
the period 1993 to 2011. This would invariably have led to
Figure 1 Kaplan Meier survival curves for RA patients showing the relationship between baseline serum levels of metalloproteinase
(MMP)-8 and mortality due to respiratory disease or pneumonia alone. (A) Respiratory disease. (B) Pneumonia alone. For these analyses,
the levels of MMP-8 were divided into those below (<) or equal to and above (≥) the median (20.07 ng/ml).
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different treatment regimes based on the severity of dis-
ease at baseline, and during follow up. It is possible that
different treatments may have resulted in different effects
on MMP levels, but it was not possible to control for this
in this study. Previous studies have indicated that the use
of oral steroids is associated with increased morbidity and
mortality from lower respiratory tract infections [12,47],
and we have found in a separate, previously described
population of well-characterised RA patients [48] that
those taking oral steroids have significantly higher levels of
MMP-8 and MMP-9 than those not taking these drugs
(unpublished observations). We have also confirmed in
this second population that MMP-8 levels are associated
with mortality from pneumonia, but this was independent
of steroid use, which did not demonstrate a significant
association (unpublished observations).
The interpretation of death certificate data is another
potential limitation to the current study, especially
with regard to deaths from pneumonia or chest infec-
tions when the associated or contributing cause (for
example, stroke) may in fact be the main cause. How-
ever, in the current study the majority of patients
dying from pneumonia (n = 23/29) had this as the only
cause, or the primary cause alongside RA as an asso-
ciated cause. These patients also demonstrated a highly
significant association of MMP-8 levels with mortality,
similar to the total group who died from pneumonia
(data not shown).
Another possible limitation was the measurement of
MMP levels at a single time point, and cumulative mea-
sures of MMP-8 levels during follow up may possibly
have provided better predictive information. Importantly
the association of MMP-8 levels with mortality was
independent of traditional measures of inflammation. In
the present study, single measurements of ESR and CRP
at study entry were not generally predictive of mortality
in models that also contained MMP-8 levels.
Conclusion
Our results indicate that in patients with established RA,
high serum levels of MMP-8 are predictive of respira-
tory disease-related mortality, and provide additional
predictive information on mortality in RA, which is not
provided by traditional measures. These results also
point to MMP-8 as a possible therapeutic target to
reduce protease-mediated damage in pneumonia and
other respiratory diseases in patients with RA.
Additional material
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rheumatoid arthritis at baseline.
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